tbuckley/cabot-search huggingface dataset:
AB1171 Use of bone marrow cells (BMCS) added to platelet-rich plasma (PRP) for treatment of bone degenerative processes in jia patient: 18-month follow-up
Authors: M.G. Alpigiani, P. Salvati, S. Rosina, S. Callegari, G. Tripodi, R. Lorini, M.B. Michelis, S. Boero
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In Regenerative Medicine one or more regenerative factors can be applied inside a cartilagine or bone defect to obtain a more rapid and complete healing. Bone Marrow Cells (BMC) added to Platelet-Rich Plasma (PRP) contain stromal cells which can differentiate in osteoclasts and osteoblasts and can be able to form osteogenic tissue and to repair bone defects secondary to degenerative processes. <h3>Methods</h3> We report on a 15-year and 8 month-old boy, followed at our Department, affected by JIA since he was 2 years old. He presented a systemic form, evolved into a polyarticular form, treated with steroids and immunosuppressor drugs. The patient had a good response to treatment with Enbrel, which he is still taking. In January 2009, he presented right hip pain and functional limitation. In July 2009 he underwent MRI of the hip joints which showed osteonecrosis in chondral/subchondral regions at the superior-external convexity of the right femoral head. We recommended deambulation with crutches and no weight bearing. Because of the persistence of joint symptoms, in July 2010 we implanted BMC plus PRP in the osteonecrotic region with improvement of pain and mobilization. In October 2010, he presented left hip pain. MRI showed focal osteonecrosis in subchodral region of left femoral head convexity. For this reason, we made a second BMC plus PRP implantation in the left hip. The last MRI, made on January 2012, showed any changes concerning the morphology of femoral heads and subchondral erosions but our patient autonomous walks, without joint pain and with improved ankle movements, since January 2011; he keeps on Enbrel and NSAIDs. <h3>Conclusions</h3> To the best of our knowledge, there are no literature data on the use of BMC plus PRP in pediatric patients affected by JIA. Considering the obvious limitations of our single case report, we observed a good short-term outcome. Therefore, follow-up is essential to check if BMC plus PRP implantation represents only a palliative care to delay surgical treatment or if it is a valid alternative to traditional orthopedic surgery. <h3>References</h3> Gothard D et al. In search of the skeletal stem cell: isolation and separation strategies at the macro/micro scale for skeletal regeneration. Lab Chip. 2011 Apr 7; 11(7): 1206-20. Epub 2011 Feb 25. Nauth A et al. Growth factors: beyond bone morphogenetic proteins. J Orthop Trauma. 2010 Sep; 24 (9): 543-6. Calori GM et al. Bone morphogenetic proteins and tissue engineering: future directions. Injury. 2009 Dec; 40 Suppl 3: S67-76. <h3>Disclosure of Interest</h3> None Declared
GLOMERULAR FUNCTION DEPENDS ON THE PERIOD OF CYANOSIS IN ADULT PATIENTS WITH TETRALOGY OF FALLOT
Authors: Tomoaki Murakami, Tomohiro Nawa, Masahiro Shiraishi, Kouji Higashi, Shigeru Tateno, Yasutaka Kawasoe, Koichiro Niwa
Journal: Journal of the American College of Cardiology (2016)
P1050 LONG-TERM OUTCOME OF SEQUENTIAL THERAPY WITH LAMIVUDINE FOLLOWED BY INTERFERON IN NUCLEOSIDE-NAIVE, HEPATITIS B E ANTIGEN-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B VIRUS GENOTYPE C INFECTION
Authors: M. Enomoto, S. Nishiguchi, A. Tamori, S. Uchida-Kobayashi, S. Iwai, H. Morikawa, Y. Murakami, H. Jomura, S. Shiomi, N. Kawada
Journal: Journal of Hepatology (2014)
Case 16-2015
Authors: Elaine Wyllie, Sandra P. Rincon, Virginia M. Pierce
Journal: New England Journal of Medicine (2015)

A 9-year-old girl presented to the emergency department with loss of consciousness and a seizure. She had returned from a trip to Puerto Rico 3 weeks earlier. Unilateral inguinal lymphadenopathy was present, and rapidly progressive encephalopathy developed.
Abstract B11: Cyclin D1 overexpression antagonizes Notch inhibition in the esophageal squamous epithelium
Authors: Momo Nakagawa, Gabrielle Wong, Shinya Ohashi, Mitsuteru Natsuizaka, Maria E. Vega, Doug B. Stairs, Anil K. Rustgi
Journal: Cancer Research (2009)

Abstract Cyclin D1 overexpression is common in esophageal squamous cell carcinoma (ESCC) and other squamous cell cancers. Notch signaling is implicated in cell proliferation and differentiation, and may act as a tumor suppressor. While squamous differentiation is maintained in ESCC and its precursor lesions, the role of Notch in esophageal carcinogenesis remains elusive. The role of genetic interactions between cyclin D1 and the Notch signaling were explored in this study. Immortalized human esophageal cells EPC2-hTERT (keratinocytes) were retrovirally transduced with tetracycline-regulatable (tet-cyclin D1. Notch was activated by the Notch1 intracellular domain and inhibited by dominant negative mastermind-like1 (DN-MAML1), a genetic pan-Notch inhibitor. Notch activity was assessed by a 8xCSL-luciferase reporter assay. Quantitative RT-PCR, Western blotting and immunohistochemistry were performed. The squamous epithelium was reconstituted in organotypic (3-D) culture, a form of tissue engineering. Notch activation led to inhibition of cell proliferation and terminal differentiation in EPC2-hTERT with a robust induction of involucrin (an early differentiation marker). By contrast, DN-MAML1 inhibited the ICN-induced CSL-dependent transcriptional activity and Notch target genes, including Hey1, Hes5 as well as involucrin. In organotypic culture, the parental EPC2-hTERT cells formed a well-organized stratified squamous epithelium. In organotypic culture, DN-MAML did not affect basal cell proliferation, but severely impaired squamous maturation and terminal differentiation with loss of filaggrin expression (a late differentiation marker) in the suprabasal layer. In 3-D culture, Cyclin D1 overexpression resulted in basal cell hyperplasia and antagonized the DN-MAML1 effect. Thus, cyclin D1 appears to stimulate cell proliferation while restraining the Notch-mediated squamous differentiation. Citation Information: Cancer Res 2009;69(23 Suppl):B11.
Recent Trends in Incidence and Treatment of Prostate Cancer Among Elderly Men
Authors: R. K. Severson, J. E. Montie, A. T. Porter, R. Y. Demers
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Recent Trends in Incidence and Treatment of Prostate Cancer Among Elderly Men Get access Richard K. Severson, Richard K. Severson Division of Epidemiology, Michigan Cancer Foundation, Detroit; and Departments of Family Medicine and Community Medicine, Wayne State University School of MedicineDetroit Search for other works by this author on: Oxford Academic PubMed Google Scholar James E. Montie, James E. Montie Department of Urology, Wayne State University School of Medicine Search for other works by this author on: Oxford Academic PubMed Google Scholar Arthur T. Porter, Arthur T. Porter Department of Radiation Oncology, Wayne State University School of Medicine Search for other works by this author on: Oxford Academic PubMed Google Scholar Raymond Y. Demers Raymond Y. Demers Division of Epidemiology, Michigan Cancer Foundation: and Department of Family Medicine, Wayne State University School of Medicine Correspondence to: Richard K. Severson, Ph.D., Division of Epidemiology, Michigan Cancer Foundation, 110 E. Warren Ave., Detroit, MI 48201 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 7, 5 April 1995, Pages 532–534, https://doi.org/10.1093/jnci/87.7.532 Published: 05 April 1995 Article history Received: 05 August 1994 Revision received: 24 January 1995 Accepted: 31 January 1995 Published: 05 April 1995
Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer
Authors: John P. Thomson, Raffaele Ottaviano, Elif B. Unterberger, Harri Lempiäinen, Arne Muller, Remi Terranova, Robert S. Illingworth, Shaun Webb, Alastair R.W. Kerr, Marcus J. Lyall, Amanda J. Drake, C. Roland Wolf, Jonathan G. Moggs, Michael Schwarz, Richard R. Meehan
Journal: Cancer Research (2016)

Abstract Aberrant hypermethylation of CpG islands (CGI) in human tumors occurs predominantly at repressed genes in the host tissue, but the preceding events driving this phenomenon are poorly understood. In this study, we temporally tracked epigenetic and transcriptomic perturbations that occur in a mouse model of liver carcinogenesis. Hypermethylated CGI events in the model were predicted by enrichment of the DNA modification 5-hydroxymethylcytosine (5hmC) and the histone H3 modification H3K27me3 at silenced promoters in the host tissue. During cancer progression, selected CGIs underwent hypo-hydroxymethylation prior to hypermethylation, while retaining H3K27me3. In livers from mice deficient in Tet1, a tumor suppressor involved in cytosine demethylation, we observed a similar loss of promoter core 5hmC, suggesting that reduced Tet1 activity at CGI may contribute to epigenetic dysregulation during hepatocarcinogenesis. Consistent with this possibility, mouse liver tumors exhibited reduced Tet1 protein levels. Similar to humans, DNA methylation changes at CGI in mice did not appear to be direct drivers of hepatocellular carcinoma progression, rather, dynamic changes in H3K27me3 promoter deposition correlated strongly with tumor-specific activation and repression of transcription. Overall, our results suggest that loss of promoter-associated 5hmC in liver tumors licenses reprograming of DNA methylation at silent CGI during progression. Cancer Res; 76(10); 3097–108. ©2016 AACR.
Abstract 374: Development of tumor-targeted near infrared dyes for fluorescence guided surgery
Authors: Lindsay E. Kelderhouse, Venkatesh Chelvam, Charity Wayua, Mahalingam M. Sakkarapalayam, Scott Poh, Sumith A. Kularatne, Philip S. Low
Journal: Cancer Research (2012)

Abstract Surgical resection of malignant disease is currently one of the most common and effective cancer treatments. Unfortunately, quantitative tumor resection is limited by a surgeon's ability to distinguish diseased tissue from adjacent healthy tissue. Fluorescence guided surgery has emerged as a tool to aid surgeons in the identification and removal of malignant tissue. While non-targeted fluorescent dyes injected near the primary tumor mass have been shown to passively accumulate in tumors and lymph nodes, the resulting tumor to background ratios are often poor and boundaries between malignant and normal tissue difficult to define. To circumvent these problems, our lab has developed high affinity tumor-specific ligands that can bind to either the prostate specific membrane antigen (PSMA) or the folate receptor (FR); i.e. cell surface molecules that are over-expressed on a number of cancers. In this study, we link these tumor targeting ligands to near infrared (NIR) dyes and explore their use in fluorescence guided surgery. In vitro, all FR and PSMA targeted NIR dyes were found to have binding affinities in the low nanomolar range. Binding was quantitatively blocked with 100-fold excess of free ligand. Upon injection into mice with metastatic disease, the targeted NIR dyes allowed clear distinction of tumor tissue from adjacent healthy tissue. Surgical resection could be conducted until all fluorescent tissue was removed. All resected fluorescent lesions were later confirmed by histology to be malignant. Of the NIR dyes tested, the 800 nm dyes were found to have the greatest fluorescence intensity through porcine tissue, indicating their superior ability to reveal buried tumor nodules. Collectively, these tumor-specific NIR dyes demonstrate significant potential for use in fluorescent guided surgery by aiding in the complete resection of diseased tissue. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 374. doi:1538-7445.AM2012-374
Fluorodeoxyglucose Positron Emission Tomography Excludes Pericardial Metastasis by Recurrent Lung Cancer
Authors: Nasrin V. Ghesani, Xinhui Sun, Hongming Zhuang, Joseph W. Sam, Abass Alavi
Journal: Clinical Nuclear Medicine (2003)

Fluorodeoxyglucose (FDG) positron emission tomography (PET) has been shown to be useful in the diagnosis and staging of a variety of malignancies. Because of its high sensitivity, FDG PET frequently detects malignant lesions that are not demonstrated clearly by anatomic imaging modalities. FDG PET usually has high negative predictive value and, therefore, negative studies are highly suggestive of a benign process. The authors present a patient in whom transesophageal echocardiography and magnetic resonance imaging described pericardial metastasis from a recurrent lung cancer, which on FDG PET was shown correctly to suggest benign scar tissue.
Case 5-2009
Authors: Daniela Kroshinsky, John H. Stone, Donald B. Bloch, Alireza Sepehr
Journal: New England Journal of Medicine (2009)

A 47-year-old woman was seen in the rheumatology clinic because of numbness and pain in the legs, which had begun 2 years earlier, intermittent swelling of the legs, and a rash. Testing for antinuclear antibodies was negative, and skin biopsies had not yielded a diagnosis. Examination of the skin revealed mottled discoloration over the lower legs; tender, erythematous nodules over the lateral malleoli; and decreased sensation to light touch over both feet. A diagnostic procedure was performed.
P152 Pulmonary Embolism Rule-out Criteria in Clinical Practice
Authors: PR Scully, M McLoughlin, D Dewar, J Gossage, E Aitken, J Dunn
Journal: Thorax (2013)

<h3></h3> Suspected pulmonary embolism (PE) is a common reason for referral to the medical team on call. The pulmonary embolism rule-out criteria (PERC) is a validated scoring system to identify patients at low risk of PE, allowing for possible discharge from the Emergency Department (ED) prior to referral. It is potentially advantageous over the modified Well9s score (MWS) for PE, as a D-dimer result is not required. We aimed to investigate two practice models: the PERC and the MWS in the investigation of suspected PE. Those patients referred to the medical team on call by the University Hospital Lewisham ED with a suspected PE were identified over a 3 month period (January to March 2012). Further information was gathered on each patient by review of their ED notes. Patients who did not meet all 8 PERC criteria or had a MWS &gt;4 were considered to be at high risk for PE. 94 patients were identified. The mean age was 53 years (range 18–92) and 68 were female (72%). 9 PEs were diagnosed. 13/94 patients met all PERC criteria, among these no PEs were diagnosed. This group underwent 10 D-dimer tests (70% positive), 2 CTPAs, and 3 V/Q scans. The overall length of stay directly related to waiting for these tests was 6 days, with a mean admission length of 1.3 days per patient.When all PERC criteria were not met due to age (&gt;50 years) alone, the D-dimer proved an excellent 9rule-out9 test, as the 2 patients in this cohort with PEs, had strongly positive D-dimer results. Using MWS, 32/94 patients scored &gt;4. Among this group there were 4 confirmed PEs (13%) and 1 indeterminate V/Q result. In the 62 patients with a MWS =4 there were also 4 confirmed PEs (6%), each with a positive D-dimer. PERC is a useful scoring system to identify patients unlikely to have a PE and seems advantageous over the MWS in terms of reducing unnecessary admissions and investigations, while maintaining patient safety. When the PERC criteria are not met due to age alone, a negative D-dimer may also be an effective 9rule-out9 option.
For an Influenza Vaccine, Are Two Bs Better Than One?
Authors: Lindsey R. Baden
Journal: New England Journal of Medicine (2013)

Every year, influenza causes epidemic disease. Periodically, antigenic drift and shift enable influenza viruses to evade human immunity from prior seasons, increasing the severity of the associated illnesses. Since the 1918 pandemic, circulating influenza A viruses have had several antigenic shifts, resulting, for example, in the emergence of the A/H2N2 (1957–1958) and A/H3N2 (1968–1969) strains, but influenza more often drifts with modest antigenic changes.1,2 A recent analysis has shown that a few specific point mutations near the hemagglutinin-receptor binding site of A/H3N2 and both circulating B lineages (B/Yamagata and B/Victoria) allow evasion of immunity.2 A central part of the . . .
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Authors: John T. Walkup, Michael J. Labellarte, Mark A. Riddle, Daniel S. Pine, Laurence Greenhill, Rachel Klein, Mark Davies, Michael Sweeney, Howard Abikoff, Sabine Hack, Brian Klee, James McCracken, Lindsey Bergman, John Piacentini, John March, Scott Compton, James Robinson, Thomas O'Hara, Sherryl Baker, Benedetto Vitiello, Louise Ritz, Margaret Roper
Journal: New England Journal of Medicine (2001)

Drugs that selectively inhibit serotonin reuptake are effective treatments for adults with mood and anxiety disorders, but limited data are available on the safety and efficacy of serotonin-reuptake inhibitors in children with anxiety disorders.
Vinyl Chloride: Can the Worker Be Protected?
Authors: David H. Wegman, John M. Peters, Rudolph J. Jaeger, William A. Burgess, Leslie I. Boden
Journal: New England Journal of Medicine (1976)

IntroductionOver 80 million American men and women spend one quarter of their lives in a workplace outside the home. The deterioration in health quality that results from exposure to hazards in their workplace is not widely known. The annual toll of job-related injuries is estimated at 2.2 million, and these injuries result in 14,000 deaths.1 The National Health Survey has estimated that the average worker experiences six days of absence and more than 16 days of restricted activity because of some type of job-related disability per year and that one out of eight workers will receive a job-related injury . . .
P5-06-09: Acquired Sensitivity to TRAIL Mediated Apoptosis in Lapatinib Resistant SKBR3 Cells.
Authors: AJ Eustace, BC Browne, M McDermott, C Gallagher, W Watson, J Crown, N O'Donovan
Journal: Cancer Research (2011)

Abstract Introduction Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor is approved for the treatment of trastuzumab-refractory HER2 positive metastatic breast cancer. However, not all HER2 positive tumors respond to lapatinib and patients who initially respond frequently relapse. Understanding the molecular alterations associated with acquisition of lapatinib resistance may lead to the identification of targets to overcome resistance. Thus, the aim of this study was to examine changes in apoptosis in a model of acquired lapatinib resistance. Methods SKBR3 cells were treated with 250 nM lapatinib twice weekly for 6 months to establish the lapatinib resistant cell line SKBR3-L. The effects of TNF-related apoptosis-inducing ligand (TRAIL) and tumour necrosis factor-α (TNF-α) on cell survival and apoptosis induction were examined in SKBR3 and SKBR3-L cells, using the acid phosphatase proliferation assay and the terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay. Cleavage of poly ADP ribose polymerase (PARP) was used to confirm apoptosis. TRAIL-1 and TRAIL-2 receptor expression were measured by flow cytometry (FACS). Results In SKBR3-L cells, TRAIL treatment (25 ng/ml) significantly inhibited cell survival (94.0 ± 12.0 %) compared to the SKBR3 cells (11.0 ± 2.2%). Treatment with TNF-α (0.5 ng/ml) also resulted in significant inhibition of cell survival (68.2 ± 10.1 %) in SKBR3-L cells compared to SKBR3 cells (9.4 ± 9.0 %). TRAIL (25 ng/ml) induced a low level of apoptosis in SKBR3 cells (7.0 ± 4.0%), whereas in SKBR3-L cells, TRAIL (25 ng/ml) induced significant apoptosis (54.8 ± 2.6%, p &amp;lt; 0.001), as determined by the TUNEL assay. We confirmed by western blotting that TRAIL treatment for 72 hours resulted in higher levels of PARP cleavage in SKBR3-L cells compared to SKBR3 cells. Both western blotting and FACS analysis of TRAIL receptor expression showed that neither TRAIL-1 nor TRAIL-2 receptor expression was significantly elevated in SKBR3-L cells compared to SKBR3 cells. Conclusions SKBR3-L cells, a model of acquired lapatinib resistance, display significant sensitivity to TRAIL induced apoptosis compared to the parental cell line SKBR3. Thus, targeting TRAIL may represent a novel therapeutic strategy to overcome acquired lapatinib resistance. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-06-09.
1156 USE OF EPOETIN BETA IN HEPATITIS C PATIENTS: SAFETY DATA FROM THE FRENCH TRIAL NEOS - INTERIM ANALYSIS AT SIX MONTHS
Authors: F. Roudot-Thoraval, M. Bourlière, A. Tran, F. Habersetzer, D. Larrey, V. Di Martino, D. Guyader, S. Metivier, S. Rouanet, V. Cartier, J.-P. Bronowicki
Journal: Journal of Hepatology (2012)
AB1133 The quality of life of children with juvenile idiopathic arthritis treated with etanercept in combination with methotrexate
Authors: E. Alexeeva, S. Valiyeva, T. Bzarova, K. Isayeva, R. Denisova, T. Sleptsova, E. Mitenko, A. Fetisova, N. Tsurikova, A. Chomakhidze
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) - a severe, chronic, steadily progressive disease leading to early disability of patients and decreasing the QOL. The use of biologic agents for treatment of JIA, can achieve a prolonged remission of the disease and improves a prognosis. The QOL is one of the most important performance criteria of the therapy. <h3>Objectives</h3> To assess the QOL of children with JIA treated with etanercept. <h3>Methods</h3> 25 patients with JIA aged 8 (6, 11) years were enrolled into the study: 8 boys and 17 girls, 17of them with polyarthritis, 8 with oligoarthritis. Etanercept was administered subcutaneously twice per week at a dose of 0.4 mg/kg (maximum 25 mg), all patients received methotrexate at a dose of 15 mg/m<sup>2</sup>/week. The assessment of the QOL was carried out by child and parent versions of the general questionnaire PedsQL Generic Core Scale and the Childhood Health Assessment Questionnaire (CHAQ). <h3>Results</h3> Following the patients and children assessment of QOL before the administration of etanercept the QOL in patients with JIA was significantly lower than in healthy children. Statistically significant increase in the QOL has been achieved within 4 weeks of etanercept therapy, 92% of patients improved overall score of the QOL by PedsQL questionnaire (self report from 53 to 59, according to proxy report from 49 to 60, p&lt;0.001). Index of Functional Disability decreased in 2 times - from 2.0 to 1.0 according to CHAQ in 3 months after treatment, and was equal to 0 by 48 weeks of observation. By self-report the QOL improved physical functioning on a scale from 40 to 88 (p&lt;0.001), on emotional functioning scale - from 60 to 89 (p&lt;0.001), on a scale of social functioning - from 82 to 100 (p&lt;0.001). After 12 months from the start of etanercept administration the level of the QOL for 68% of patients with JIA have been consistent with the same level of healthy children. <h3>Conclusions</h3> Etanercept treatment significantly improves the QOL of children with JIA, reduces the negative impact of illness on the lives of children, improving physical activity and emotional state of patients, allows sick children to communicate more with other children of the same age. <h3>Disclosure of Interest</h3> None Declared